Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABA(A) potentiating activity for use in dementia

por Luo, Jia, Lee, Sue H., VandeVrede, Lawren, Qin, Zhihui, Piyankarage, Sujeewa, Tavassoli, Ehsan, Asghodom, Rezene T., Aissa, Manel Ben, Fà, Mauro, Arancio, Ottavio, Yue, Lan, Pepperberg, David R., Thatcher, Gregory R. J.
Publicado 2015

Inhibition of Fast Axonal Transport by Pathogenic SOD1 Involves Activation of p38 MAP Kinase

por Morfini, Gerardo A., Bosco, Daryl A., Brown, Hannah, Gatto, Rodolfo, Kaminska, Agnieszka, Song, Yuyu, Molla, Linda, Baker, Lisa, Marangoni, M. Natalia, Berth, Sarah, Tavassoli, Ehsan, Bagnato, Carolina, Tiwari, Ashutosh, Hayward, Lawrence J., Pigino, Gustavo F., Watterson, D. Martin, Huang, Chun-Fang, Banker, Gary, Brown, Robert H., Brady, Scott T.
Publicado 2013